Xenetic Biosciences, Inc. (XBIO:NASDAQ) closed at $1.82 on October 27, 2026, up 6.08% on the day. The stock trades 63.1% below its 52-week high of $4.94 and 15.5% above its 52-week low of $1.58. Over the past year, it lost 50.7%. Xenetic Biosciences, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 27, 2025, XBIO closed higher on 115 days (46%). Its best day was March 16, 2026 (+20.37%) and its worst was September 16, 2026 (-48.71%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 3 times.
Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and planned commercialization of human drug therapies for the treatment of various conditions. Its drug delivery platform systems include PolyXen for creating next generation biologic drugs; OncoHist for the development of oncology drugs focused on orphan indications; Virexxa for the treatment of progesterone receptor negative endometrial cancer; and ImuXen for the development of vaccines that can simultaneously deliver multiple active pharmaceutical ingredients. Its product candidates comprise ErepoXen, a polysialylated erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease; and OncoHist, an orphan drug that is in pre-clinical stage of development for the treatment of refractory acute myeloid leukemia. The company is also developing a pipeline of drug candidates for next generation biologics and novel oncology therapeutics in various orphan disease indications. It has a research, development, license, and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation for Factor VIII to treat hemophilia; a collaborative...
Find more stocks like XBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.